Julio Chirinos, MD
Cardiovascular Disease · Philadelphia, PANPI 1215140686
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $137,982 of the $145,139 with a category attached, or 95.1%. 8 manufacturers reported payments, led by Merck at 26.6% of the total. Reporting peaked in 2023 at $53,233 and has fallen 96.4% since, to $1,937 in 2025. Among cardiovascular disease clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 43 payments — averaging $3375.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$39K
- Fukuda Denshi Co., Ltd.$30K
- Bayer$29K
- E.r. Squibb & Sons, L.L.C.$20K
- Edwards Lifesciences$20K
- Janssen Research & Development, LLC$8K
- plus $290 from 2 others
Across 1 payment — averaging $112,821 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Fukuda Denshi Co., Ltd.$113K
What the payments were for
- Consulting fees$137,98295%
- Speaking & faculty fees$2,2502%
- Travel & lodging$4,2343%
- Food & beverage$6730%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 8 | $38,647 |
| Fukuda Denshi Co., Ltd.(2 entities) | 6 | $29,584 |
| Bayer | 3 | $28,608 |
| E.r. Squibb & Sons, L.L.C. | 4 | $20,240 |
| Edwards Lifesciences | 17 | $19,970 |
| Janssen Research & Development, LLC | 2 | $7,800 |
| Amgen | 2 | $262 |
| Siemens Medical Solutions USA, Inc. | 1 | $28 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VS-2000$28,834
- Non-Covered$9,331
How this compares
$145,139 in reported general payments places this provider in the 95th percentile of 1,250 cardiovascular disease providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other cardiovascular disease in Philadelphia
- Paul ForfiaPhiladelphia$1.2M
- Quang BuiPhiladelphia$933K
- Dean KaralisPhiladelphia$385K
- Manavendra BakhshiPhiladelphia$250K
- Philip HainesPhiladelphia$170K
- Michael MillerPhiladelphia$133K
- Nehal MehtaPhiladelphia$129K
- Garo GaribianPhiladelphia$115K
- Norman FeinsmithPhiladelphia$94K
- Brian DrachmanPhiladelphia$78K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.